Home/Research library/Teichman et al. (2006)
Study in humans · 2006 · cited for CJC-1295 with DAC

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. The Journal of clinical endocrinology and metabolism 2006;91(3):799-805. doi:10.1210/jc.2005-1536 · PubMed 16352683

In brief

CJC-1295 is a growth-hormone-releasing-hormone analogue engineered to bind albumin after injection so that it lasts days rather than minutes. In the first study healthy adults received a single subcutaneous dose at one of four levels or placebo; in the second they received two or three weekly or fortnightly doses. After one injection, mean growth hormone rose two- to ten-fold for six days or more and IGF-I rose one-and-a-half- to three-fold for nine to eleven days, with the increase depending on dose. The estimated half-life was 5.8 to 8.1 days. After repeated doses, IGF-I stayed above baseline for up to 28 days. No serious adverse reactions were reported, and the authors judged the compound safe and relatively well tolerated at the lower doses studied.

Study design

Two randomised, placebo-controlled, double-blind, ascending-dose trials of 28 and 49 days in healthy adults aged 21 to 61, subcutaneous injection.

What it does not show

Short studies in healthy volunteers with hormone levels as the endpoint. The compound here is the albumin-binding (DAC) form; the paper does not cover the non-DAC fragment often sold under a similar name, and it reports no functional or long-term outcome.

A clinical trial tests a pharmaceutical form of a compound, in a defined patient group, under medical supervision, with a defined endpoint. None of that transfers to a research-grade vial, and this page does not suggest it does.

Where this paper is cited

  • CJC-1295 with DAC — Healthy adults: a single dose raised growth hormone for at least six days and IGF-1 for nine to eleven days; estimated half-life 5.8–8.1 days.

Other papers cited for CJC-1295 with DAC

Further reading

How this page was made: the citation was retrieved from PubMed by PMID and checked against the title on the product page; the summary was written from the paper's abstract and reports only what the abstract reports. Read the paper itself before relying on any figure here.

Research use only This page summarises a published paper. It is not a claim that any product sold by Zyrna Research does what the paper describes, the trial used a pharmaceutical product under medical supervision, and nothing here is dosing guidance. Nothing sold by Zyrna Research is for human or veterinary use.